Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | IO Biotech Aktie: Positiver Kursverlauf | 378 | Börse Global | Das Biotech-Unternehmen präsentiert neue Forschungsergebnisse bei AACR 2025 und erhält Anerkennung für innovative Ansätze in der Immunonkologie-Therapie. IO Biotech hat kürzlich bedeutende Fortschritte... ► Artikel lesen | |
Mo | IO Biotech, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
25.03. | IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting | 1 | GlobeNewswire (USA) | ||
05.03. | IO Biotech stock retains Buy rating, $12 target at H.C. Wainwright | 10 | Investing.com | ||
04.03. | IO Biotech on track with cancer vaccine BLA for 2025 | 3 | Investing.com | ||
04.03. | IO Biotech auf Kurs für Krebsimpfstoff-Zulassungsantrag bis 2025 | 7 | Investing.com Deutsch | ||
04.03. | IO Biotech Reports 2024 Business Highlights | 121 | GlobeNewswire (Europe) | Preparations for submission of a Biologics License Application (BLA) for Cylembio® (imsapepimut and etimupepimut, adjuvanted) to FDA by year end 2025 remain on track. The trial completed enrollment... ► Artikel lesen | |
IO BIOTECH Aktie jetzt für 0€ handeln | |||||
04.03. | IO Biotech, Inc. - 8-K, Current Report | - | SEC Filings | ||
04.02. | IO Biotech advances cancer vaccine candidate IO112 | 3 | Investing.com | ||
04.02. | IO Biotech treibt Krebsimpfstoff-Kandidaten IO112 voran | 25 | Investing.com Deutsch | ||
04.02. | IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate | - | GlobeNewswire (USA) | ||
09.01. | IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer | 145 | GlobeNewswire (Europe) | -- Enrollment Completed Ahead of Schedule -- -- Initial Data Expected in 2025 -- NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
27.12.24 | IO Biotech, Inc. - 8-K, Current Report | - | SEC Filings | ||
26.12.24 | Medizinischer Leiter von IO Biotech erwirbt Stammaktien im Wert von 26.553 US-Dollar | 9 | Investing.com Deutsch | ||
24.12.24 | IO Biotech, Inc. (NASDAQ:IOBT) CEO Acquires $10,125.00 in Stock | 4 | MarketBeat | ||
20.12.24 | IO Biotech announces up to €57.5M debt financing from the European Investment Bank | 5 | Seeking Alpha | ||
20.12.24 | IO Biotech secures €57.5 million EIB loan for cancer vaccines | 1 | Investing.com | ||
20.12.24 | IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank | 1 | GlobeNewswire (USA) | ||
16.12.24 | IO Biotech, Inc. - 8-K, Current Report | - | SEC Filings | ||
12.11.24 | IO Biotech, Inc. - 10-Q, Quarterly Report | - | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PALATIN TECHNOLOGIES | 0,492 | +0,20 % | Palatin: Bremelanotide-Tirzepatide Combination Achieves Primary Endpoint In Phase 2 Obesity Study | WASHINGTON (dpa-AFX) - Palatin Technologies Inc. (PTN) announced that its BMT-801 Phase 2 obesity co-administration study met its primary endpoint and was highly statistically significant. The... ► Artikel lesen | |
BIOXXMED | 0,800 | +107,25 % | XETR DELETION OF INSTRUMENTS FROM XETRA - 31.03.2025 | The following instruments on Xetra do have their last trading day on 31.03.2025.Die folgenden Instrumente auf Xetra haben ihren letzten Handelstag am 31.03.2025.ISIN NameDE000A4BGGE4 bioXXmed AG ► Artikel lesen | |
ORGANOVO | 2,140 | 0,00 % | Organovo, Inc.: Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements | SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches... ► Artikel lesen | |
OCUGEN | 0,597 | -6,14 % | Ocugen: Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200-a Novel Fusion Protein for Diabetic Macular Edema | OCU200 has a very favorable safety and tolerability profileNo serious adverse events related to the study drug have been reportedDosing of the second cohort has been approved MALVERN, Pa., March 18... ► Artikel lesen | |
SIRONA BIOCHEM | 0,037 | -100,00 % | XFRA ZSB: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILSIRONA BIOCHEM CORP.... ► Artikel lesen | |
BIO-GATE | 0,760 | 0,00 % | Bio-Gate: Vielversprechende Wachstumschancen | Nach Darstellung der Analysten Matthias Greiffenberger und Cosmin Filker von GBC hat die Bio-Gate AG im Geschäftsjahr 2024 (per 31.12.) einen leichten Umsatzrückgang verbucht, besitzt aufgrund der innovativen... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,662 | -5,43 % | Kursraketen und Übernahmefantasie! Steyr Motors, Evotec und Defence Therapeutics! | Steyr Motors reitet jetzt nicht nur die Rüstungs-, sondern auch die Übernahmewelle. Nach der Kooperationsmeldung mit einer Rheinmetall-Tochter ist der Nischenwert zum Shootingstar geworden. Allerdings... ► Artikel lesen | |
VAXART | 0,347 | +6,17 % | Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the "Company" or "Vaxart") today announced that on March 24, 2025, the independent members of the Board... ► Artikel lesen | |
CELLECTAR BIOSCIENCES | 0,280 | -0,71 % | Cellectar Biosciences: Multibagger mit Ansage? | Cellectar Biosciences (WKN: A3DQSD) heißt unsere Top-Spekulation der Stunde. Das auf Radiopharmaka gegen Krebs spezialisierte Biotechunternehmen konnte gestern eine wichtige Einigung mit der US-Gesundheitsbehörde... ► Artikel lesen | |
BURCON NUTRASCIENCE | 0,059 | -0,67 % | Burcon NutraScience Corporation: Burcon Integrates Protein Technologies at Galesburg Facility | Vancouver, British Columbia--(Newsfile Corp. - April 1, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development of... ► Artikel lesen | |
AFFIMED | 0,930 | -100,00 % | Affimed N.V.: Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting | MANNHEIM, Germany, March 25, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,... ► Artikel lesen | |
IMMUNIC | 0,943 | -8,27 % | EQS-News: Immunic AG: Immunic, Inc. to Participate in Scientific and Industry Conferences in April | Issuer: Immunic AG
/ Key word(s): Conference
Immunic, Inc. to Participate in Scientific and Industry Conferences in April
01.04.2025 / 12:30 CET/CEST
The issuer is solely... ► Artikel lesen | |
AIM IMMUNOTECH | 0,105 | 0,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space Expected milestones over... ► Artikel lesen | |
T2 BIOSYSTEMS | 0,080 | -1,48 % | T2 Biosystems, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | ||
CEL-SCI | 0,197 | +0,77 % | CEL-SCI Aktie: Risiken mehren sich | CEL-SCI hat am 18. März 2025 den Abschluss eines Finanzierungsangebots in Höhe von 2,5 Millionen Dollar bekannt gegeben. Dabei wurden 16 Millionen Stammaktien oder vorfinanzierte Optionsscheine ausgegeben.... ► Artikel lesen |